Compare JPMorgan Equity Premium Income ETF (JEPI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Repligen Corporation Common Stock — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.97 (market cap $45.69B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 4.1× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Repligen Corporation Common Stock for 0 Days on average.
| JEPI | RGEN | |
|---|---|---|
Market Cap | $45.69B | $11.14B |
Volume | 3,633,306 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $194.57 |
52-Week Low | $55.29 | $102.87 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93 with minimal daily movement (-0.05%) and maintains a bullish technical outlook based on moving averages. The ETF continues its consistent dividend distribution strategy with recent payments of $0.37 per share. Technical indicators show mixed signals with RSI levels ranging from neutral to overbought, while the overall trend remains positive.
The covered-call strategy provides income stability but may limit upside during strong market rallies. Recent media coverage highlights JEPI's role in retirement income strategies, though investors should consider tax implications and income limitations compared to pure equity exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
